Special Issue

Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development: 2nd Edition

Message from the Guest Editor

Neutralizing antibodies play a key role in evaluating the effectiveness of SARS-CoV-2 vaccines. There is an urgent need for standardized in vitro potency methods to assess antiviral products in both pre-clinical and clinical phases. Detecting neutralizing antibodies against SARS-CoV-2 can help understand the protective immune response in COVID-19 patients and asymptomatic cases. Currently, there are various methods for detecting SARS-CoV-2 neutralizing antibodies, but differences in laboratory procedures can lead to incomparable results. This makes it difficult to compare the immunogenicity of different vaccines. To gain a better understanding of recent scientific knowledge and current trends in SARS-CoV-2 neutralization assay and vaccine development, this Special Issue focuses on recent scientific and technical progress in this field. This Special Issue welcomes original research articles and reviews covering recent advances in novel neutralization assay development, standardization and comparison of different SARS-CoV-2 neutralization assays, comparison of neutralizing antibody responses induced by different vaccines, and correlates of protection.

Guest Editor

Dr. Jianhui Nie
Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China

Deadline for manuscript submissions

closed (31 March 2025)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/205938

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI